Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aimmune Therapeutics (AIMT) Reports AR101 Demonstrates Consistent Efficacy & Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
November 8, 2019 7:16 AM ESTAimmune Therapeutics, Inc. (NASDAQ: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent efficacy and safety with AR101 across the phase 3 PALISADE and ARTEMIS trials, despite differing regions of study, entry criteria, therapeutic dosing periods and primary efficacy endpoints. The data were presented at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.
The study comparison found substantially and significantly higher proportions of AR101-treated patients were able to tolerate clinically meaningful quantities of peanut... More
